Skip to main content
Consumer Site
TylenolProfessional

September 11-8, 2026 | Las Vegas, Nevada

Mark your calendar for PAINWeek 2026!

Join us as we introduce our NEW product innovation TYLENOL® with Naproxen! A first-of-its-kind OTC combination. Now FDA approved.​

Register here

Introducing TYLENOL® with Naproxen

A first-of-its-kind OTC combination to expand what's possible in pain management.

Learn more

Schedule

Activity

Host/Co-Presenters

Date/Time​

Exhibition: Booth #400​

TYLENOL®​

Wednesday - 9/9​

  • 8:30am-9:30am​

  • 3:30pm-6:30pm​

Thursday - 9/10​

  • 8:30am-11am​

  • 3:30pm-7pm​

Breakfast Symposium: “Double Down on Pain Relief: A New Option for Multimodal Approaches to Pain Relief”​

  • Mark P. Garofoli, PharmD, MBA, BCGP, CPE, CTTS – West Virginia University & West Virginia University Medicine​

  • Sergey M. Motov, MD, FAAEM – Maimonides Medical Center​

  • Daniel Budnitz, MD, MPH – Kenvue Brands LLC​

Tuesday - 9/8

  • 8:30am – 9:30am ​

Expert Roundtable: “Double Down on Pain Relief: A New Fixed-Dose Combination for Pain Management”​

  • Dr. Paul Desjardins, DMD, PhD – Rutgers School of Dental Medicine​

  • Dr. Jeffrey Gudin, MD – University of Miami Miller School of Medicine​

  • Theresa Mallick-Searle, NP – Standford Health Care​

  • Daniel Budnitz, MD, MPH – Kenvue Brands LLC​

  • Dr. Jorge Cruz, MD, MS – Kenvue Brands LLC​

  • Marsha Tharakan, MD, DDS – Kenvue Brands LLC​

Wednesday - 9/9

  • 2:40pm – 4:00pm ​

Closing Ceremony: Festive Vegas-inspired red and gold celebration​

TYLENOL®​

Thursday - 9/10

  • 5:30pm – 9:30pm​

Scientific Poster Presentations

Poster Title

Authors

Abstract Link

#36: National Survey of Pharmacists' Practices in OTC Pain Management​

  • Maria Eppel, PharmD, MBA – Kenvue Brands LLC​

  • Julia A. Gleason, PharmD, RPh – Kenvue Brands LLC​

  • Michelle Jo, PharmD – Kenvue Brands LLC​

See Abstract 36

#81: A Phase 3 Multiple-dose Efficacy and Safety Trial of a Novel Fixed Dose Combination of Acetaminophen and Naproxen Sodium in a Post-surgical Bunionectomy Pain Model​

  • Marsha Tharakan, MD, DDS – Kenvue Brands LLC​

  • Steven Sacavage, PharmD – Kenvue Brands LLC​

  • Daniel Budnitz, MD, MPH – Kenvue Brands LLC​

See Abstract 81

#82: Pharmacokinetic and Mechanistic Rationale for Combining Acetaminophen with Naproxen Sodium: A Systematic Analysis of Temporal and Mechanistic Complementarity​

​

  • Robin A. Mathew, PhD – Kenvue Brands LLC​

  • Sergey Motov, MD - Maimonides Medical Center​

  • Sandy Tian, PhD – Kenvue Brands LLC​

  • Jeffrey Gudin, MD - University of Miami, Miller School of Medicine​

  • James A. McGuire, MS – Kenvue Brands LLC​

  • Daniel Budnitz, MD, MPH – Kenvue Brands LLC​

  • Alankar Gupta, MD, MBA – Kenvue Brands LLC​

See Abstract 82

#83: Analgesic Effectiveness of a New Fixed-Dose Combination Acetaminophen/Naproxen Sodium: A Phase 3 Placebo-controlled, Randomized, Double-blind, Factorial Trial in Post-operative Dental Pain​

  • Daniel Budnitz, MD, MPH – Kenvue Brands LLC​

  • Steven Sacavage, PharmD -– Kenvue Brands LLC​

  • Tom Ding, MS – Kenvue Brands LLC​

  • Anna T. Hader, PhD – Kenvue Brands LLC​

  • Marsha Tharakan, MD, DDS – Kenvue Brands LLC​

  • Andrew Myers, MD – Kenvue Brands LLC​

  • Leslie Bloom, MS – Kenvue Brands LLC​

  • James A. McGuire, MS – Kenvue Brands LLC​

  • Todd Bertoch, MD – CenExel​

  • Rajesh Mishra, MD, PhD – Kenvue Brands LLC​

See Abstract 83